基于免疫信息学方法设计针对黄花蒿过敏原Art an 7的T细胞表位疫苗OA
Design of a T-cell Epitope Vaccine Against Artemisia annua Allergen Art an 7 Using Immunoinformatics Approaches
源自黄花蒿(Artemisia annua)花粉的主要过敏原Art an 7是导致中国北方地区花粉症的重要过敏原之一,在蒿属花粉过敏患者中具有非常高的致敏率(约90%).研究表明,基于T细胞表位的疫苗(T-cell epitope vac-cine,TEV)在缓解过敏性疾病方面显示出良好效果,但目前尚无针对黄花蒿花粉过敏原TEV的报道.为了开发针对Art an 7的TEV,采用免疫信息学工具预测Art an 7的理化性质以及B细胞表位和T细胞表位;选择两个与主要组织相容性复合体Ⅱ类分子(major histocompatibility complex class Ⅱ,MHC-Ⅱ)具有高亲和力的T细胞表位(RAITFEPATGKTVKE和GKTVKEFPVLPGGSR)用于构建TEV;使用GPGPG接头连接上述两个T细胞表位,并通过EAAAK接头将Toll样受体4(Toll-like receptor 4,TLR4)激动剂RS04佐剂偶联于TEV蛋白的氨基端和羧基端,形成完整的疫苗结构;随后采用免疫信息学工具分析所设计TEV的抗原性、致敏性、毒性、理化特性、二级和三级结构及其与免疫受体的对接.结果显示,TEV与人类白细胞抗原DRβ1链(human leuko-cyte antigen DR beta 1,HLA-DRB1)和TLR4均表现出较强的结合能力和稳定的相互作用,而且其可以在人体内诱发免疫反应.综上所述,本研究设计的TEV可用作黄花蒿过敏原特异性免疫疗法的候选疫苗,但其有效性有待进一步实验验证.
Art an 7,the primary allergen derived from Artemisia annua pollen,is one of the major allergens causing pollinosis in Northern China,with a very high sensitization rate(approximately 90%)among patients allergic to Artemisia pollen.Studies have shown that T-cell epitope vaccines(TEVs)exhibit remarkable effi-cacy in alleviating allergic diseases.However,there are currently no reports on a TEV targeting A.annua pollen allergens.To develop a TEV against Art an 7,the major allergen of A.annua pollen,immunoinfor-matics tools were used to predict the physicochemical properties,as well as B-cell and T-cell epitopes of Art an 7.Two T-cell epitopes(RAITFEPATGKTVKE and GKTVKEFPVLPGGSR)with high affinity for ma-jor histocompatibility complex class Ⅱ(MHC-Ⅱ)molecules were selected for TEV construction.These two T-cell epitopes were connected using a GPGPG linker,and the Toll-like receptor 4(TLR4)agonist RS04 adjuvant was conjugated to the N-and C-termini of the TEV protein via an EAAAK linker to form the complete vaccine structure.Subsequently,immunoinformatics tools were used to analyze the designed TEV,including its antigenicity,allergenicity,toxicity,physicochemical properties,secondary and tertiary struc-tures,as well as its docking with immune receptors.The results showed that the TEV exhibited strong binding capacity and stable interactions with both human leukocyte antigen DR beta 1(HLA-DRB1)and TLR4,and could induce an immune response in the human body.In summary,the TEV designed in this study may be used as a candidate vaccine for allergen-specific immunotherapy against A.annua.However,the efficacy of this vaccine requires further experimental validation.
王宁;宣鹏飞;杨敬平
内蒙古医科大学第三临床医学院,中国内蒙古包头 014010内蒙古包钢医院,中国内蒙古包头 014010内蒙古医科大学第三临床医学院,中国内蒙古包头 014010||内蒙古包钢医院,中国内蒙古包头 014010
生物科学
花粉过敏黄花蒿Art an 7免疫信息学表位疫苗过敏原特异性免疫疗法(AIT)
pollen allergyArtemisia annuaArt an 7immunoinformaticsepitopevaccineallergen-spe-cific immunotherapy(AIT)
《生命科学研究》 2026 (4)
351-361,11
"十四五"社会公益领域重点研发和成果转化计划项目(2022YFSH0017)内蒙古医科大学科技百万工程(联合)项目(YKD2022LH056)
评论